NCT04335136: A reported trial by Apeiron Biologics
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04335136 |
|---|---|
| Title | Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19 |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | April 30, 2020 |
| Completion date | Dec. 26, 2020 |
| Required reporting date | Dec. 26, 2021, midnight |
| Actual reporting date | June 7, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |